Navigation Links
Next 10 years crucial to ensure provision of clean water for future generations
Date:6/5/2008

The world needs to develop a means of securing the supply of clean fresh water within the next 10 years if we are to tackle looming water shortages, leading expert on water purification and director of the US National Science Foundation's Science and Technology Centre for Advanced Materials for the Purification of Water, Dr Mark Shannon, is expected to warn top scientists, government, industrialists, academics and business people in a speech at the 2nd Global Innovation Imperatives (Gii) conference to be held in New Delhi, India, on 19-20 June 2008.

Organised by the Society of Chemical Industry (SCI) and the American Chemical Society (ACS), and co-organised by PHD Chamber, the Gii program was officially launched earlier this year in New Orleans to tackle some of the big issues affecting mankind, the first of which is water.

Never has the need for humankind to ensure the supply of clean, drinking water for future generations been greater.

Already, food shortages have led to fierce fighting and unrest in parts of the world water shortages triggered by climate change, population growth and poor water management may be next unless tackled now.

Since 1900, the world's population has tripled and is expected to rise by another 50% within the next 50 years. India is home to one sixth of the world's population. It is estimated that two thirds of its population does not have access to proper sanitation and that 2.1million children die by the age of five due to lack of clean water.

SCI chief executive Andrew Ladds says: "Water availability, supply and quality are issues facing every one of us the recent unprecedented move to ship clean drinking water to Barcelona to tackle the city's worst drought in decades may be a herald of things to come.

"I believe that science and innovation are the keys to finding a solution. We are increasingly part of a global community and we must call on this community to work together,
'/>"/>

Contact: Meral Nugent
meral.nugent@soci.org
44-020-759-81533
Society of Chemical Industry
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Viacom to Receive Leadership Award for Business Excellence from The Global Business Coalition on HIV/AIDS, Tuberculosis and Malaria for Its 25 Years of Work on HIV/AIDS Education and Advocacy
2. New model predicts whether patients will be free of renal cancer 12 years after initial treatment
3. Healthcare Industry Spending on Telecommunications Services Hits $55 Billion Over Next Five Years, Says Insight Research
4. Fitworks Fitness Centers Responds to the Growing Adolescent Obesity Rate by Offering Free Summer Memberships to Teens 13-15 Years of Age
5. Study: Child maltreatment victims lose 2 years of quality of life
6. Lifestyle Changes Can Keep Diabetes at Bay for 14 Years
7. A New Report on Home Telehealth and Remote Patient Monitoring Says Current Market is Close to $5.6 billion and Growth of Up to 70% is Expected to Continue Over the Next Few Years
8. Premature tooth loss can affect oral health for years to come
9. New report on telehealth says market is expected to grow over next few years
10. After Collecting 22 Million Petition Signatures on myLifetime.com, Bipartisan Breast Cancer Patient Protection Act Gets First Congressional Hearing in 12 Years
11. Study: Patients 75 years and older with brain tumors may benefit from more aggressive treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)... SAN FRANCISCO, Jan. 8 M... that David Hung, M.D., president and chief,execu... Morgan Healthcare,Conference on Wednesday, Janua...t. Francis Hotel in San Francisco. , Dr. Hu...clinical,development programs for Dimebon for Alz...
(Date:1/8/2009)...HINGTON, Jan. 8 The Pew...son has been named director, chemical and food saf...olicy program. Olson, who was formerly deputy staf...ttee on Environment and Public Works, brings nearl...nd consumer advocacy to Pew. , , "We are excit...
(Date:1/8/2009)...ould be used when assessing traditional risk facto...althDay News) -- Two molecular signs -- or "biomar...ation when trying to assess a person,s risk of str... or very low risk, adding these markers does not c...ay Nambi, a cardiologist at the Methodist DeBakey ...
(Date:1/8/2009)...hy Tune Promoted to Principal. Christine Siu and ..., MINNEAPOLIS, SAN FRANCISCO and STAMFORD, Conn.,...tners, a health care venture capital firm that inv...ies, today announced the promotion of three member...moted to Principal. Christine Siu and Jason Brown...
Breaking Medicine News(10 mins):Health News:Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference 2Health News:Veteran Environmental Health Expert Erik D. Olson to Join Pew 2Health News:Inflammation Markers May Help Predict Stroke Risk 2Health News:Inflammation Markers May Help Predict Stroke Risk 3Health News:Thomas, McNerney & Partners Promotes Three Members of Its Investment Team 2
... to findings of a recent study , 70 percent of all... ill individuals.// Researchers studied nearly 43,...p homes to explore the correlation between patient...nd drug use. Results showed 28 percent of patients...
...rs now say they’ve found one drug that may success...cer.// In a study of 22 patients with breast, pros...42 percent had their tumors either stabilize or sh...y , it turns off one of the switches within the ca...
...of a new study shows that high-doses of vitamin E...erall risk of early death.// Vitamin E is one of ...wth and function. On average, dietary intake of vi...y. Other sources of the vitamin include wheat germ...
...rs say there may be a new way to correct hard-to-t...g during a minimally // invasive surgical procedur...ure a more complete correction. Birthmarks basica...le with the birthmarks do not experience problems,...
Other Medicine News:
(Date:1/6/2009)...swire-FirstCall/ -- , - Early Renewal of th...ember 2011 , - Expansion of the Scope of th...Ophthalmology , - Revised Commercial Terms ...o a Third Party , ExonHit Therapeutics (A...of its existing drug discovery collaboration with ...
(Date:12/30/2008)...ewswire/ -- The Coalition for 21st Century Medicin...enentech, Inc. on December 5, 2008, seeking to res...tic tests to physicians and patients. The request...arm patient care and rests on flawed scientific an...s to encourage the research, development, and comm...
(Date:12/17/2008)...t and validation of non-animal alternative test me...re/ -- MatTek Corporation today announced that the...ed the scientific validity of the Modified EpiDerm...g. ESAC concluded that the Modified EpiDerm SIT h...diction of skin irritating and non-irritating test...
(Date:12/17/2008)...l/ -- Delcath Systems, Inc. (Nasdaq: DCTH ) toda...h.D., to Delcath,s Board of Directors. Dr. Contag...perience working with international and domestic i....com/cgi-bin/prnh/20081118/NY46990LOGO ) , ,... 2006 and served as CEO. Prior to starting Cobalt...
Breaking Medicine Technology:ExonHit Therapeutics Expands Strategic Collaboration With Allergan 2ExonHit Therapeutics Expands Strategic Collaboration With Allergan 3ExonHit Therapeutics Expands Strategic Collaboration With Allergan 4Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients 2Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients 3Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients 4EpiDerm's Skin Irritation Test Fully Validated in European Union 2Delcath Adds Dr. Pamela R. Contag to Its Board of Directors 2Delcath Adds Dr. Pamela R. Contag to Its Board of Directors 3Dragon retains leading investor relations firm 3999 1Dragon retains leading investor relations firm 3999 2Dragon retains leading investor relations firm 3999 3QuoNova Global Executive Appointments 3994 1QuoNova Global Executive Appointments 3994 2QuoNova Global Executive Appointments 3994 3QuoNova Global Executive Appointments 3994 4Fludarabine Mitoxantrone and Zevalin 28R 29 Produces 96 25 Complete Remission Rate in First Line Treatment of Patients with Follicular Non Hodgkins L 1531 1Fludarabine Mitoxantrone and Zevalin 28R 29 Produces 96 25 Complete Remission Rate in First Line Treatment of Patients with Follicular Non Hodgkins L 1531 2Fludarabine Mitoxantrone and Zevalin 28R 29 Produces 96 25 Complete Remission Rate in First Line Treatment of Patients with Follicular Non Hodgkins L 1531 3Fludarabine Mitoxantrone and Zevalin 28R 29 Produces 96 25 Complete Remission Rate in First Line Treatment of Patients with Follicular Non Hodgkins L 1531 4New Brain Fitness Training Promotes Health and Independence of Long Term Care Insurance Policyholders 14470 1New Brain Fitness Training Promotes Health and Independence of Long Term Care Insurance Policyholders 14470 2New Brain Fitness Training Promotes Health and Independence of Long Term Care Insurance Policyholders 14470 3
...ries, Inc. Today,Announced the Top Line Results of...) Study with the Compound Desmoteplase , Aachen (G...k,Exchange, Prime Standard: PA8) and its US partne...unced topline results of,the DIAS-2 (Desmoteplase ...Desmoteplase. The Phase III study was designed to,...
...tCall/ - Research,collaborators with Oncolytics Bi... a poster presentation covering REOLYSIN(R),clinic...Oncology,(ASCO) Annual Meeting, to be held June 1-...f Oncolytics, U.K. Phase I systemic,administration... Phase I Study of,Wild-Type Oncolytic Reovirus Adm...
Other Medicine Technology:Top Line Results of Phase III Study in Acute Ischemic Stroke,(DIAS-2) Do Not Demonstrate Difference Between Desmoteplase and,Placebo 2Top Line Results of Phase III Study in Acute Ischemic Stroke,(DIAS-2) Do Not Demonstrate Difference Between Desmoteplase and,Placebo 3Top Line Results of Phase III Study in Acute Ischemic Stroke,(DIAS-2) Do Not Demonstrate Difference Between Desmoteplase and,Placebo 4Oncolytics Biotech Inc.'s Research Collaborators to Present,REOLYSIN Clinical Trial Data at ASCO Conference 2
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
Medicine Products: